F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

NCT05468294 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: F16IL2
DRUG: Nivolumab, fixed dose

Sponsor

Philogen S.p.A.